GSK's (GSK) Hold Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reaffirmed its “hold” rating on GSK and maintained a GBX 2,000 price target, implying approximately 7.5% upside from the current share price.
• Analyst sentiment remains mixed but leans toward “hold”: GSK has a consensus rating of Hold and an average price target of GBX 2,064.38, based on two Buy, five Hold, and one Sell rating.
• GSK shares traded around GBX 1,860.50, while recent company results showed quarterly earnings of GBX 10.80 per share, a 14.52% net margin, and a 28.35% return on equity.

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday, Digital Look reports. They presently have a GBX 2,000 price objective on the stock. Deutsche Bank Aktiengesellschaft's price objective points to a potential upside of 7.50% from the company's current price.

A number of other research firms have also commented on GSK. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th. Jefferies Financial Group reaffirmed a "buy" rating and issued a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Finally, Berenberg Bank boosted their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a research report on Tuesday, September 15th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, GSK has a consensus rating of "Hold" and an average price target of GBX 2,064.38.

GSK Stock Performance

Shares of LON GSK traded up GBX 0.50 during mid-day trading on Tuesday, reaching GBX 1,860.50. 64,601,094 shares of the company were exchanged, compared to its average volume of 13,178,364. The company's 50-day simple moving average is GBX 1,887.04 and its 200-day simple moving average is GBX 1,946.62. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 103.36. The stock has a market capitalization of £74.55 billion, a P/E ratio of 15.79, a P/E/G ratio of 1.24 and a beta of 0.29. GSK has a twelve month low of GBX 1,520.50 and a twelve month high of GBX 2,282.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, research analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In other news, insider Jonathan Symonds bought 1,500 shares of the company's stock in a transaction on Friday, September 18th. The shares were purchased at an average price of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal bought 637 shares of the company's stock in a transaction on Friday, September 18th. The stock was bought at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Over the last 90 days, insiders have acquired 2,144 shares of company stock worth $6,009,566. Company insiders own 0.20% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.